Month: June 2022

WESTPORT, Conn., June 27, 2022 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced that it has been added to the Russell 2000® and 3000® Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US stock market opens today. “We’re pleased to be joining the Russell 2000 and 3000 Indexes, which is an important milestone for CODI and provides us with enhanced visibility in the public markets,” said Elias Sabo, CEO of Compass Diversified. “We look forward to continuing our strong momentum as we execute on our strategy that is delivering excellent operational and financial results, while driving increased value for shareholders.” The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of...

Students, teachers and tribal communities to have reliable access to 1 Gigabit speeds to enhance learning WASHINGTON, June 27, 2022 (GLOBE NEWSWIRE) — Verizon announced today plans to enhance connectivity to approximately 80 Bureau of Indian Education (BIE) and tribally-operated schools located on 64 Indian reservations across 23 states. Verizon’s network investment across diverse tribal lands is expected to connect nearly 42,000 Native American students, leading to reliable, high-speed Internet service and connected devices for students in the impacted states. The work will support BIE’s mission to provide quality education opportunities from early childhood through life in accordance with a tribe’s needs for cultural and economic well-being. Working closely with BIE, Verizon had previously upgraded existing 100MB...

NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the initiation of patient screening in its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical trial of EDSIVO™ (celiprolol) for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS). “With no approved treatments available for vEDS, ongoing clinical evaluation of EDSIVO™ (celiprolol) is an important step that we hope could lead to the first available treatment option for this fatal disorder,” said Adrian Quartel, MD, FFPM, Chief Medical Officer of Acer. “The...

BERKELEY, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (“Rigetti” or “the Company”) (NASDAQ: RGTI), a pioneer in hybrid quantum-classical computing systems, today announced the Company is set to join the Russell 3000® Index. Inclusion is scheduled to take place at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022, according to the final list of additions posted June 24, 2022. “Inclusion in the Russell 3000® Index is an exciting development as we work to highlight Rigetti’s pioneering role in the quantum computing industry,” said Chad Rigetti, Founder and CEO. “Just as classical computing has been a long-term driver of economic growth, we believe the same dynamic will hold true for quantum computing in the years and decades ahead. We are moving...

ALLEN, Texas, June 27, 2022 (GLOBE NEWSWIRE) — PFSweb, Inc. (Nasdaq: PFSW) (the “Company”), a global commerce services company, will join the broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of May 6, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. “Joining the Russell 3000® Index further...

HENDERSON, Nev., June 27, 2022 (GLOBE NEWSWIRE) — P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced it has been added as a member of the Russell 3000® Index, effective after the U.S. market opens on June 27, as part of the 2022 Russell indexes reconstitution. This year’s reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 6, 2022, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as applicable, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective,...

1PointFive plans to use the approximately 27,000 acres to expand its carbon sequestration hub business HOUSTON, June 27, 2022 (GLOBE NEWSWIRE) — 1PointFive, a subsidiary of Occidental’s (NYSE: OXY) Low Carbon Ventures (OLCV) business, and Manulife Investment Management today announced that OLCV and Manulife entered into a lease agreement for approximately 27,000 acres of timberland in Western Louisiana. The agreement provides 1PointFive with access to subsurface pore space and surface rights to develop and operate a carbon sequestration hub, with access to permanently store industrial carbon emissions. Two Class VI injection permits, required by the EPA for geologic sequestration, have already been filed for the site. The lease agreement is a pivotal step in 1PointFive’s strategic vision to develop carbon capture and sequestration...

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results entitled, “Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective In Chemotherapy-Induced Pain,” during the opening oral session of the International Cannabinoid Research Society (ICRS) Symposium. “Our pre-clinical research showed that chronic, oral treatment with ART26.12,...

PARAMOUNT, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Tattooed Chef, Inc. (Nasdaq: TTCF) (“Tattooed Chef” or the “Company”), a leader in plant-based foods, announced today that it was added to the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. “Tattooed Chef’s addition to the Russell Microcap® Index offers an exciting opportunity to elevate our Company’s profile among investors and enhance our visibility,” said Sam Galletti, President and CEO of Tattooed...

– No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date – – Early Indications of Efficacy in Assessable Patients at Multiple Dose Levels – NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a clinical update on the ongoing Phase 1 dose-escalating clinical trial of GFH009, its novel and highly selective CDK9 inhibitor, in advanced relapsed and refractory lymphoma and acute myeloid leukemia (AML). In the AML group, patients treated at the 22.5 mg dose level experienced no dose limiting toxicities, including no grade 3/4 neutropenias...